TRP_1170x120_3-8-19

Dr. Corey McCann

Sandoz and Pear Therapeutics announce launch of reSET

Sandoz and Pear Therapeutics announce launch of reSET

HOLZKIRCHEN— Sandoz, a Novartis division, and Pear Therapeutics, Inc., announced today the commercial launch of reSET for patients with Substance Use Disorder (SUD). reSET, the first and only FDA-authorized prescription digital therapeutic, is immediately available. Study results from a multicenter, randomized clinical trial showed that reSET, when used with outpatient therapy and contingency management, significantly improved abstinence